Literature DB >> 25503729

Effects of hydration in rats and mice with polycystic kidney disease.

Katharina Hopp1, Xiaofang Wang1, Hong Ye1, María V Irazabal1, Peter C Harris1, Vicente E Torres2.   

Abstract

Vasopressin and V2 receptor signaling promote polycystic kidney disease (PKD) progression, raising the question whether suppression of vasopressin release through enhanced hydration can delay disease advancement. Enhanced hydration by adding 5% glucose to the drinking water has proven protective in a rat model orthologous to autosomal recessive PKD. We wanted to exclude a glucose effect and explore the influence of enhanced hydration in a mouse model orthologous to autosomal dominant PKD. PCK rats were assigned to normal water intake (NWI) or high water intake (HWI) groups achieved by feeding a hydrated agar diet (HWI-agar) or by adding 5% glucose to the drinking water (HWI-glucose), with the latter group used to recapitulate previously published results. Homozygous Pkd1 R3277C (Pkd1(RC/RC)) mice were assigned to NWI and HWI-agar groups. To evaluate the effectiveness of HWI, kidney weight and histomorphometry were assessed, and urine vasopressin, renal cAMP levels, and phosphodiesterase activities were measured. HWI-agar, like HWI-glucose, reduced urine vasopressin, renal cAMP levels, and PKD severity in PCK rats but not in Pkd1(RC/RC) mice. Compared with rat kidneys, mouse kidneys had higher phosphodiesterase activity and lower cAMP levels and were less sensitive to the cystogenic effect of 1-deamino-8-d-arginine vasopressin, as previously shown for Pkd1(RC/RC) mice and confirmed here in Pkd2(WS25/-) mice. We conclude that the effect of enhanced hydration in rat and mouse models of PKD differs. More powerful suppression of V2 receptor-mediated signaling than achievable by enhanced hydration alone may be necessary to affect the development of PKD in mouse models.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  cAMP; cyclic nucleotide phosphodiesterase; hydration; polycystic kidney disease; vasopressin

Mesh:

Substances:

Year:  2014        PMID: 25503729      PMCID: PMC4312959          DOI: 10.1152/ajprenal.00345.2014

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  32 in total

1.  Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

Authors:  Xiaofang Wang; Vincent Gattone; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

2.  Somatic inactivation of Pkd2 results in polycystic kidney disease.

Authors:  G Wu; V D'Agati; Y Cai; G Markowitz; J H Park; D M Reynolds; Y Maeda; T C Le; H Hou; R Kucherlapati; W Edelmann; S Somlo
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.

Authors:  Christopher J Ward; Marie C Hogan; Sandro Rossetti; Denise Walker; Tam Sneddon; Xiaofang Wang; Vicky Kubly; Julie M Cunningham; Robert Bacallao; Masahiko Ishibashi; Dawn S Milliner; Vicente E Torres; Peter C Harris
Journal:  Nat Genet       Date:  2002-02-04       Impact factor: 38.330

4.  A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD).

Authors:  Markus Moser; Sonja Matthiesen; Jutta Kirfel; Hubert Schorle; Carsten Bergmann; Jan Senderek; Sabine Rudnik-Schöneborn; Klaus Zerres; Reinhard Buettner
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

Review 5.  The regulation of vasopressin function in health and disease.

Authors:  G L Robertson
Journal:  Recent Prog Horm Res       Date:  1976

Review 6.  Urea and urine concentrating ability: new insights from studies in mice.

Authors:  Baoxue Yang; Lise Bankir
Journal:  Am J Physiol Renal Physiol       Date:  2005-05

7.  Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.

Authors:  V H Gattone; R L Maser; C Tian; J M Rosenberg; M G Branden
Journal:  Dev Genet       Date:  1999

8.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

9.  Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Xiaofang Wang; Qi Qian; Stefan Somlo; Peter C Harris; Vincent H Gattone
Journal:  Nat Med       Date:  2004-02-29       Impact factor: 53.440

10.  Influence of plasma amino acid level on vasopressin secretion.

Authors:  F Schmitt; J L Bresson; N Beressi; D G Bichet; D Chauveau; L Bankir
Journal:  Diabetes Metab       Date:  2003-09       Impact factor: 6.041

View more
  28 in total

1.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

3.  Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Authors:  Vicente E Torres; Eiji Higashihara; Olivier Devuyst; Arlene B Chapman; Ronald T Gansevoort; Jared J Grantham; Ronald D Perrone; John Ouyang; Jaime D Blais; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-23       Impact factor: 8.237

4.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

5.  Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.

Authors:  Anyi Wang; Takuo Hirose; Yusuke Ohsaki; Chika Takahashi; Emiko Sato; Ikuko Oba-Yabana; Satoshi Kinugasa; Yoshikazu Muroya; Sadayoshi Ito; Takefumi Mori
Journal:  Clin Exp Nephrol       Date:  2018-11-13       Impact factor: 2.801

6.  Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

7.  Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies.

Authors:  Hong Ye; Xiaofang Wang; Caroline R Sussman; Katharina Hopp; Maria V Irazabal; Jason L Bakeberg; Wells B LaRiviere; Vincent C Manganiello; Charles V Vorhees; Haiqing Zhao; Peter C Harris; Jan van Deursen; Christopher J Ward; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

8.  Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Marie E Edwards; Fouad T Chebib; Maria V Irazabal; Troy G Ofstie; Lisa A Bungum; Andrew J Metzger; Sarah R Senum; Marie C Hogan; Ziad M El-Zoghby; Timothy L Kline; Peter C Harris; Frank S Czerwiec; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-19       Impact factor: 8.237

Review 9.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

Review 10.  Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Fouad T Chebib; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-26       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.